Marine Jary

1.9k total citations · 1 hit paper
52 papers, 796 citations indexed

About

Marine Jary is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Marine Jary has authored 52 papers receiving a total of 796 indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 14 papers in Surgery. Recurrent topics in Marine Jary's work include Colorectal Cancer Treatments and Studies (15 papers), Gastric Cancer Management and Outcomes (11 papers) and Pancreatic and Hepatic Oncology Research (9 papers). Marine Jary is often cited by papers focused on Colorectal Cancer Treatments and Studies (15 papers), Gastric Cancer Management and Outcomes (11 papers) and Pancreatic and Hepatic Oncology Research (9 papers). Marine Jary collaborates with scholars based in France, Belgium and United States. Marine Jary's co-authors include Christophe Borg, Stéfano Kim, Olivier Adotévi, Thierry André, Magali Svrcek, Julie Henriques, Christophe Tournigand, Antoine Adenis, Christophe Louvet and Romain Cohen and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and Journal of Hepatology.

In The Last Decade

Marine Jary

47 papers receiving 787 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study

2022 220 citations Thierry André, David Tougeron et al. Journal of Clinical Oncology profile →

Peers

Marine Jary

ONCOL

PRM

SURGE

IMMUN

Giovanni Randon Italy

Takashi Ichimura Japan

Myung Hee Chang South Korea

Takahiro Einama Japan

Do Hyoung Lim South Korea

Lara Alessandrini Italy

Masako Asayama Japan

Andrea Schlemmer Austria

Stéfano Kim France

Kohei Shigeta Japan

Giovanni Randon Italy

Marine Jary

673 ×1.5

ONCOL

361 ×1.1

PRM

183 ×0.7

SURGE

145 ×0.9

IMMUN

140 ×1.2

Citations per year, relative to Marine Jary Marine Jary (= 1×) peers Giovanni Randon

Countries citing papers authored by Marine Jary

Since Specialization

Citations

This map shows the geographic impact of Marine Jary's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marine Jary with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marine Jary more than expected).

Fields of papers citing papers by Marine Jary

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marine Jary. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marine Jary. The network helps show where Marine Jary may publish in the future.

Co-authorship network of co-authors of Marine Jary

This figure shows the co-authorship network connecting the top 25 collaborators of Marine Jary. A scholar is included among the top collaborators of Marine Jary based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marine Jary. Marine Jary is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Robb, William B., Julie Véziant, Laëtitia Dahan, et al.. (2025). What are the outcomes for long-term survivors after esophagectomy ? – Evidence from a randomized controlled trial (FFCD9901). European Journal of Surgical Oncology. 51(7). 109736–109736. 1 indexed citations

Jacob, Paul, Côme Lepage, Claire Gallois, et al.. (2025). Deep Learning on Histologic Slides Accurately Predicts Consensus Molecular Subtypes and Spatial Heterogeneity in Colon Cancer. Modern Pathology. 38(11). 100877–100877. 1 indexed citations

Mourgues, Charline, Céline Lambert, Denis Pezet, et al.. (2024). French multi-institutional cost-effectiveness analysis of gemcitabine plus nab-paclitaxel versus gemcitabine alone as second-line treatment in metastatic pancreatic cancer patients. Therapeutic Advances in Medical Oncology. 16. 12704371–12704371.

Roth, Gaël S., Anna Pellat, Guillaume Piessen, et al.. (2024). A simple prognostic score to predict recurrence after pancreaticoduodenectomy for ampullary carcinoma: results from the French prospective FFCD-AC cohort. ESMO Open. 9(12). 103988–103988.

Nourrisson, Céline, L. Vercruysse, Bruno Pereira, et al.. (2024). Increased levels of anti-Encephalitozoon intestinalis antibodies in patients with colorectal cancer. PLoS neglected tropical diseases. 18(9). e0012459–e0012459.

Pereira, Bruno, et al.. (2023). Self-Medication during and after Cancer: A French Nation-Wide Cross-Sectional Study. Cancers. 15(12). 3190–3190. 1 indexed citations

Ginzac, Angeline, Émilie Thivat, Caroline Pétorin, et al.. (2023). A phase-II study based on dose adjustment according to UGT1A1 polymorphism: is irinotecan underdosed in first-line FOLFIRI regimen for mCRC?. Cancer Chemotherapy and Pharmacology. 93(3). 225–236. 3 indexed citations

André, Thierry, David Tougeron, Guillaume Piessen, et al.. (2022). Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study. Journal of Clinical Oncology. 41(2). 255–265. 220 indexed citations breakdown →

Henriques, Julie, Déwi Vernerey, Hamadi Almotlak, et al.. (2022). Interest of the Addition of Taxanes to Standard Treatment in First-Line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients. Frontiers in Oncology. 12. 763926–763926. 1 indexed citations

10.

Mansi, Laura, Laurie Spehner, Étienne Daguindau, et al.. (2021). Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients. European Journal of Cancer. 150. 1–9. 17 indexed citations

11.

Kroemer, Marie, Célia Turco, Laurie Spehner, et al.. (2020). Investigation of the prognostic value of CD4 T cell subsets expanded from tumor-infiltrating lymphocytes of colorectal cancer liver metastases. Journal for ImmunoTherapy of Cancer. 8(2). e001478–e001478. 31 indexed citations

12.

Jary, Marine, Angélique Vienot, Romain Loyon, et al.. (2020). Molecular description of ANGPT2 associated colorectal carcinoma. International Journal of Cancer. 147(7). 2007–2018. 22 indexed citations

13.

Royer, Bernard, Antonin Schmitt, Thierry Nguyen, et al.. (2020). Exposure‐response analysis of Raltitrexed assessing liver toxicity. British Journal of Clinical Pharmacology. 87(3). 1327–1337. 4 indexed citations

14.

Joseph, Elodie Lauret Marie, Caroline Laheurte, Marine Jary, et al.. (2019). Immunoregulation and Clinical Implications of ANGPT2/TIE2+ M-MDSC Signature in Non–Small Cell Lung Cancer. Cancer Immunology Research. 8(2). 268–279. 33 indexed citations

15.

Galaine, Jeanne, Célia Turco, Charline Vauchy, et al.. (2019). CD4 T cells target colorectal cancer antigens upregulated by oxaliplatin. International Journal of Cancer. 145(11). 3112–3125. 36 indexed citations

16.

Kim, Stéfano, Damien Montange, Thierry Nguyen, et al.. (2017). A simple and fast LC–MS/MS method with a very high sensitivity for the measurement of raltitrexed in human plasma. Journal of Chromatography B. 1060. 240–246. 3 indexed citations

17.

Fagnoni, Philippe, Angélique Vienot, Christophe Borg, et al.. (2017). A systematic review of economic evaluation in pancreatic ductal adenocarcinoma. European Journal of Cancer. 86. 207–216. 12 indexed citations

18.

Jary, Marine, Déwi Vernerey, Thierry Lecomte, et al.. (2015). Prognostic Value of Angiopoietin-2 for Death Risk Stratification in Patients with Metastatic Colorectal Carcinoma. Cancer Epidemiology Biomarkers & Prevention. 24(3). 603–612. 16 indexed citations

19.

Jary, Marine, François Ghiringhelli, Marion Jacquin, et al.. (2014). Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancer. Cancer Chemotherapy and Pharmacology. 74(1). 141–150. 6 indexed citations

20.

Kim, Stéfano, Marine Jary, Luigi Mansi, et al.. (2013). DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma. Annals of Oncology. 24(12). 3045–3050. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact